Heart Failure : Epidemiology, Pathophysiology, and Management of Heart Failure in Diabetes Mellitus - 02/02/18
Doi : 10.1016/j.ecl.2017.10.007
Anders Jorsal, BSc, MD, PhD a, b, Henrik Wiggers, BSc, MD, PhD, DMSc a, b, John J.V. McMurray, MD, FRCP, FESC, FMedSci, FRSE c, d, ⁎ 
a Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200 Aarhus N, Denmark
b Department of Clinical Medicine, Aarhus University, Incuba Skejby, Building 2, Palle Juul-Jensens Boulevard 82, 8200 Aarhus N, Denmark
c BHF Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, 126 University Place, Glasgow G12 8TA, UK
d Queen Elizabeth University Hospital, 1345 Govan Road, Glasgow G51 4TF, UK
∗Corresponding author. BHF Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, 126 University Place, Glasgow G12 8TA, UK.BHF Cardiovascular Research CentreInstitute of Cardiovascular and Medical SciencesUniversity of Glasgow126 University PlaceGlasgowG12 8TAUK
Résumé |
This article briefly discusses the epidemiology of heart failure and diabetes and summarizes the key findings from the recent cardiovascular outcome trials in patients with type 2 diabetes, with a focus on heart failure as an endpoint.
Le texte complet de cet article est disponible en PDF.Keywords : Cardiac function, Cardiovascular events, Glucose lowering therapy, Glycemia, Heart failure, Type 2 diabetes mellitus
Plan
| Disclosure Statement: A. Jorsal has served as a consultant for, and received lecture fees from, Novo Nordisk. H. Wiggers has been principal investigator or subinvestigator in studies involving the following pharmaceutical companies: MSD, Bayer, Daiichi-Sankyo, Novartis, Novo Nordisk, Sanofi-Aventis, and Pfizer. J.J.V. McMurray’s employer has been paid for his role on executive/steering committees, data monitoring committees, and/or endpoint committees of trials funded by Abbvie, Amgen, AstraZeneca, Bayer, BMS, Cardiorentis, DalCor, GSK, Kidney Research UK, Merck, Oxford University, Pfizer, Resverlogix, Stealth Biotherapeutics, and Theracos. |
© 2017
Elsevier Inc. Tous droits réservés.
Vol 47 - N° 1
P. 117-135 - mars 2018 Retour au numéro
Article précédent
- Cardiovascular Outcomes Trials of Glucose-Lowering Drugs or Strategies in Type 2 Diabetes
- Hertzel C. Gerstein, Reema Shah
- Personalizing Glucose-Lowering Therapy in Patients with Type 2 Diabetes and Cardiovascular Disease
- Silvio E. Inzucchi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?